Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Data Brief ; 31: 105923, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32671144

ABSTRACT

A previous investigation showed that the endometrium normalized in women with endometrial hyperplasia after three months treatment with high dose levonorgestrel IUS (intrauterine system) [1] . The effect was maintained even if immunohistochemical analyses of the endometrium showed that nuclear progesterone receptors (nPRs) were completely downregulated. These observations indicated that some type of non-genomic effect existed [2]. We conducted new investigations of endometrial hyperplasia, now with 6 months low dose levonorgestrel IUS treatment. Again, the growth disturbances were reversed with normalization of the endometrium [3,4]. In the context of these studies, RT-qPCR analyses of the endometrium were performed before and after treatment, to determine expression of nuclear progesterone receptors (nPRA+B and nPRB), membrane progesterone receptors (mPR, α-, ß- and γ-subtypes) and progesterone receptor membrane components (PGRMC1and PGRMC2). The human cervical cell line (C-4 I) [5] with no detectable nPRs [6,7] , was included in the investigation as biological control .The gene expression of nPRs, mPRs and PGRMCs was determined in the logarithmic growth phase. Tissue and cellular mRNA was determined with RT-qPCR and used as a surrogate marker for receptor (protein) expression. The present data are connected to the related article entitled "Expression of nuclear progesterone receptors (nPRs), membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in the human endometrium after 6 months levonorgestrel low dose intrauterine therapy" [8].

2.
J Steroid Biochem Mol Biol ; 202: 105701, 2020 09.
Article in English | MEDLINE | ID: mdl-32479983

ABSTRACT

The classical steroid receptors (nuclear receptors), including those for progesterone (nPRs), are thoroughly characterized. The knowledge about so-called non-genomic effects, which are mediated by extra-nuclear initiated signals, has increased immensely the last decades. In a previous clinical study of endometrial hyperplasia, we observed that the antiproliferative progestin effect persisted after 3 months treatment with levonorgestrel (LNG) intrauterine system (IUS) even with a complete downregulation of nPRs. This raised the question of what other mechanisms than signaling through nPRs could explain such an observation. In the present study, RT-qPCR was employed to characterize mRNA expression for nPRs, membrane progesterone receptors (mPRs) and progesterone receptor membrane components (PGRMCs) in women (n = 42) with endometrial hyperplasia that received intrauterine low dose LNG for 6 months. At the end of this period endometrial tissue showed that nPRs were virtually completely downregulated (≈ 10 % of baseline) whereas the levels of remaining mPRs, subtype-α, -ß and -γ were 76 %, 59 % and 73 % of baseline, respectively. PGRMC1 was downregulated to 15 % of baseline, in contrast to PGRMC2, which was upregulated to about 30 % above baseline. We used human cancer cells from uterine cervix (C-4I cells) as control. Progesterone caused a concentration-dependent antiproliferative effect but in several and separate studies, we were unable to detect nPRs (immunocytochemistry) in the C-4I cells. The use of RT-qPCR showed that nPRs were undetectable in C-4I cells, in contrast to mPRs and PGRMCs with a distinct mRNA expression. The present study suggests that mPRs and/or PGRMCs preserve the antiproliferative effect of LNG in the human endometrium and are responsible for the concentration-dependent antiproliferative effect of progesterone in C-4I cells.


Subject(s)
Contraceptive Agents, Female/therapeutic use , Endometrial Hyperplasia/drug therapy , Endometrium/metabolism , Levonorgestrel/therapeutic use , Receptors, Cell Surface/genetics , Receptors, Progesterone/genetics , Adult , Aged , Aged, 80 and over , Cell Line, Tumor , Cell Membrane/metabolism , Cell Nucleus/metabolism , Cell Proliferation/drug effects , Contraceptive Agents, Female/pharmacology , Endometrial Hyperplasia/genetics , Endometrium/pathology , Female , Gene Expression/drug effects , Humans , Levonorgestrel/pharmacology , Middle Aged , Pilot Projects
3.
Anticancer Res ; 39(9): 4897-4903, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31519593

ABSTRACT

BACKGROUND/AIM: Endometrial hyperplastic polyps (EHP) may progress to endometrial carcinoma (EC) if left untreated. We aimed to prospectively investigate the efficacy of the low-dose levonorgestrel intrauterine system (LNG-IUS) as therapy for EHP with malignant potential. PATIENTS AND METHODS: In total, 37 women with EHP underwent therapy with LNG-IUS containing 13.5 mg levonorgestrel for six months or 4-10 weeks depending on whether the EHP was characterized (by D-score analysis) as low- to medium-risk (n=33) or high-risk (n=4) of coexistent or future EC. Therapy response was defined as complete clearance of hyperplastic glands in post-therapy endometrial biopsy. RESULTS: All women with low- to medium-risk EHP obtained therapy response, whereas only 1 out of 4 with high-risk EHP responded to therapy. None of the women were diagnosed with EC during the study and no serious adverse events occurred. CONCLUSION: Low-dose LNG-IUS represents a promising therapy for selected women with EHP.


Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Endometrial Hyperplasia/drug therapy , Endometrial Hyperplasia/pathology , Polyps/pathology , Precancerous Conditions/drug therapy , Precancerous Conditions/pathology , Progestins/administration & dosage , Adult , Aged , Biomarkers , Female , Humans , Middle Aged , Pilot Projects , Progestins/adverse effects , Prospective Studies , Treatment Outcome
4.
Anticancer Res ; 38(5): 2883-2889, 2018 05.
Article in English | MEDLINE | ID: mdl-29715112

ABSTRACT

BACKGROUND/AIM: Progestin therapy has been accepted as therapy for low- and medium-risk endometrial hyperplasia. The aim of this study was to investigate the efficacy of the low-dose levonorgestrel-impregnated intrauterine system (LNG-IUS) 13.5 mg (Jaydess®, Bayer Pharmaceuticals, Berlin, Germany) as therapy for endometrial hyperplasia. PATIENTS AND METHODS: A total of 21 women with histologically-verified endometrial hyperplasia were prospectively treated with LNG-IUS Jaydess. Therapy duration was 6 months (n=16) or 3-6 weeks (n=5) depending on individual risk (low- and medium-risk versus high-risk) for co-existent or future endometrial carcinoma. Paired endometrial biopsies were sampled prior to and after therapy and classified according to the WHO94 classification system and D-score. RESULTS: All women with low- and medium risk endometrial hyperplasia had-therapy response. In the group of women with high-risk endometrial hyperplasia only 40% (two out of five) obtained a therapy response. CONCLUSION: Low-dose LNG-IUS Jaydess was proven to be an excellent therapy option for low- and medium-risk endometrial hyperplasia. For patients with high-risk endometrial hyperplasia hysterectomy or LNG-IUS therapy under close surveillance is advised.


Subject(s)
Contraceptive Agents, Female/administration & dosage , Endometrial Hyperplasia/drug therapy , Intrauterine Devices, Medicated , Levonorgestrel/administration & dosage , Adult , Cohort Studies , Female , Humans , Middle Aged , Pilot Projects , Precancerous Conditions/drug therapy , Prospective Studies
5.
Anticancer Res ; 37(5): 2529-2536, 2017 05.
Article in English | MEDLINE | ID: mdl-28476823

ABSTRACT

AIM: To investigate whether risk of relapse of endometrial hyperplasia persists many years after successful primary therapy and whether clinical or biological markers observed at primary diagnosis may predict relapse. MATERIALS AND METHODS: A series of 57 women with endometrial hyperplasia received levonorgestrel-impregnated intrauterine system or oral progestin for three months during 1998-2000. Index biopsies were classified according to WHO1994 and D-score systems, and immunohistochemical staining for estrogen receptor α (ERα), estrogen receptor ß (ERß), progesterone receptor A (PRA), progesterone receptor B (PRB), B-cell lymphoma 2/apoptosis regulator (BCL2), BCL2-associated X protein/apoptosis regulator (BAX), paired box 2 (PAX2), and phosphatase and tensin homolog (PTEN) reported as H-scores. RESULTS: Over a follow-up of 157.8 months, 23% (10/43) of patients experienced relapse. No correlation with age, body mass index, parity, WHO94 classification, or D-score was found. Only PRA (p=0.004) and PRB (p=0.038) showed certain correlation with relapse. CONCLUSION: Endometrial hyperplasia recurs many years after successful progestin therapy. Increased expression of PRB and reduced expression of PRA significantly correlated with relapse. Our results support the importance of continuous endometrial protection and the need for new clinical surveillance guidelines.


Subject(s)
Endometrial Hyperplasia/drug therapy , Levonorgestrel/therapeutic use , Medroxyprogesterone/therapeutic use , Progestins/therapeutic use , Administration, Oral , Adult , Aged , Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/therapeutic use , Endometrial Hyperplasia/metabolism , Female , Follow-Up Studies , Humans , Intrauterine Devices, Medicated , Levonorgestrel/administration & dosage , Medroxyprogesterone/administration & dosage , Middle Aged , Progestins/administration & dosage , Receptors, Progesterone/metabolism , Recurrence
SELECTION OF CITATIONS
SEARCH DETAIL
...